【本件リリース先】
文部科学記者会、科学記者会、
広島大学関係報道機関

広島大学

406 5 . . . 0
-5 343 -5 3- -
7

NEWS RELEASE

7 2 4

IL-6

IL-6
Atezo+Bev 2

IL-6
3 Atezo+Bev

Atezo+Bev
Atezo+Bev

Atezo+Bev
IL-6 Atezo+Bev

Atezo+Bev 4
Atezo+Bev 5
IL-6 Atezo+Bev
Atezo+Bev
IHI IL-6
6 CD8
T 7

IL-6 TME
Atezo+Bev
IL-6

2024 Journal of Gastroenterology

Serum IL 6 concentration is a useful biomarker to predict the efficacy of atezolizumab plus bevacizumab in patients with hepatocellular carcinoma

Ryoichi Miura[1] Atsushi Ono[1] Hikaru Nakahara[1] Yuki Shirane[1] Kenji Yamaoka[1] Yasutoshi Fujii[2] Shinsuke Uchikawa[1] Hatsue Fujino[1] Eisuke Murakami[1] Tomokazu Kawaoka[1] Daiki Miki[1] Masataka Tsuge[1] [3] Takeshi Kishi[4] Waka Ohishi[5] Naoya Sakamoto[6] Koji Arihiro[7] Clair Nelson Hayes[1] Shiro Oka[1]

1. Department of Gastroenterology, Graduate School of Biomedical and Health Sciences, Hiroshima University Hospital, Hiroshima, 734-8551, Japan.
2. Department of Clinical Oncology, Graduate School of Biomedical and Health Sciences, Hiroshima University, Hiroshima, Japan.
3. Liver Center, Hiroshima University, Hiroshima, 734-8551, Japan.
4. Biosample Research Center, Radiation Effects Research Foundation, Hiroshima, Japan.
5. Department of Clinical Studies, Radiation Effects Research Foundation, Hiroshima, Japan.
6. Department of Pathology and Clinical Laboratories, National Cancer Center-Hospital East, Kashiwa, Chiba, Japan.
7. Department of Anatomical Pathology, Hiroshima University Hospital, Hiroshima, Japan.

Journal of Gastroenterology Q1
DOI 10.1007/s00535-024-02185-w

8

Atezo+Bev

Atezo+Bev

Atezo+Bev

Atezo+Bev

IL-6 Atezo Bev IL-6 9 10

Atezo+Bev

IL-6 Atezo+Bev

IL-6

TME Atezo+Bev

IHC TME IL-6

CD8 T

IL-6

Atezo+Bev

IL-6

1 IL-6 -6

2 Atezo+Bev
8 Atezo Bev
Atezo+Bev

3

4

5

6
T

7 CD8 T T

8

9

10



1

IL-6 M2

CD163 CD8 T CD8

Atezo Bev



2 Atezo+Bev IL-6

IL-6



3　　IL-6　　CD8　CD163

IL-6　　CD8　　T
M2　　(CD163　　)
CD8/CD163
CR/PR
PD　　CD8/CD163

Tel　082-257-5191　FAX　082-257-5194
E-mail　atsushi-o@hiroshima-u.ac.jp